4
Changes in Ownership
Kalaris Therapeutics, Inc. Filed Acc 0001209191-23-053347
Chief Accounting Officer sold 715 shares at an average $1.56 ($1,116)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Hagen Brett R · Chief Accounting Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-10-19 | Sale : show line 1 in the form 10b5-1 | −358 | $1.58 | $566 | 126,595 | D |
| 2023-10-20 | Sale : show line 2 in the form 10b5-1 | −357 | $1.54 | $550 | 126,238 | D |
| Open-market sales · 715 sh · avg $1.56 · $1,116 | ||||||
Loading xslF345X05/doc4.xml…